CA1114723A - Glucose detection system free from fluoride-ion interference - Google Patents

Glucose detection system free from fluoride-ion interference

Info

Publication number
CA1114723A
CA1114723A CA307,795A CA307795A CA1114723A CA 1114723 A CA1114723 A CA 1114723A CA 307795 A CA307795 A CA 307795A CA 1114723 A CA1114723 A CA 1114723A
Authority
CA
Canada
Prior art keywords
glucose
reagent
fluoride
layer
elements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA307,795A
Other languages
French (fr)
Inventor
Glen M. Dappen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Kodak Co
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Application granted granted Critical
Publication of CA1114723A publication Critical patent/CA1114723A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • Y10T436/144444Glucose

Abstract

IMPROVED GLUCOSE DETECTION SYSTEM
FREE FROM FLUORIDE-ION INTERFERENCE
Abstract of the Disclosure An improved multilayer element for detecting glucose in samples of biological fluid which may contain with fluoride ion as a contaminant or preservative is described. The improved element comprises a buffered Trinder's reagent, which reagent comprises glucose oxidase, peroxidase, 4-aminoantipyrine and a phenolic or naphtholic coupler, which is buffered to a pH between about 4.5 and about 6Ø Such a buffering reduces any interference which may be due to fluoride ion present in the sample under analysis.

Description

The glucose oxldase method Or assaying ~or glucose used by Trinder ls well-known ln the art. Such method uses reagents, which comprise glucose oxidase, a substance havlng peroxidase activity, 4-aminoantipyrine and a phenollc cr naphtholic coupler. The method and reagents are descrlbed ln detail in: Trinder, P., Ann. Clln. Biochem., 6 (1969), 24~ and Trinder, P., J. Clin. Pathol., 22 (1969), 246.
Sod~um rluoride is used as a preservative in blood and blood serum samples whlch are to be held for an extended period Or time, i.e. up to ten days (Henry, Clinical Chemistry,
2 Ed. p. 385). Such a preservative is routlnely used at a level of 250 mg/dl Or blood or blood serum. The addition of 250 mg/dl Or sodium fluoride to blood serum has been found to decrease the apparent glucose concentratlon, as measured -utllizing multilayer elements Or the type described ln U.S. Patent No. 3,992,158 by 20-30 mg/dl at a concentration Or 200 mg glucose/dl. ~his problem is compounded by the following factors: 1) the preservative 2G is not always used and 2) when the preservative is incorporated within blood withdrawal apparatus such as ~ound ~n commerclal ; embodlments, the concentration Or preservatlve is ~nown only when the container is ~llled to capaclty. Since the containers often are not filled to capacity (owing to loss of vacuum) the sodlum rluoride concentratlon may increase as much as 2-
3 fold over the 250 mg/dl level.
In view of the variability in sodlum ~luoride con-centration which may be encountered, it is clear that a need -exlsts for a multllayer element ror the analysls of glucose whlch exhibits reduced sensitlvity to ~odlum rluoride.

,. -1- ~k -, '. ', ." ' ' : : .'':,, , . . ' . ~, . ' ., 2~

The concentratlons of fluorlde lon used for this purpose have apparently not caused noticeable lnterference with prior-art methods ror analyzlng for glucose. ~his is probably due to dllution technlques commonly used ln prlor art solution quantitative assays and the seml-quantltative character Or prior art "dry" methods ~or glucose detection.
It has been foun~ however, ~hat, when a Trinder's reagent system as described above is lncorporated lnto a multllayer element of the type described ln U.S. Patent 3,992,1~8, the fluorlde lon used as a preservative contributes a substantlal negative bias. The presence and elimlnatlon or reduction Or this bias uslng the method described herein wlll be shown in the examples below.
U.S. Patent 3,992,158 descrlbes integral multilayer elements for the detection o~ varlous biological materials, lncluding glucose. Elements the type described therein are identical to those useful ln the successful practice of the preferred embodlments hereof, and the details for preparlng such elements are readily determinable therefrom.

Ex~mple 3 Or U.S. Patent 3,992,158 descrlbes an element for the detection of glucose uslng glucose oxldase, peroxidase and an lndlcator system of the type descrlbed herein in an element slmilar to that descrlbed ln the lnstant appllcatlon. However, no pH ls speclfied for the reagent -~ ' ~ ' , . :-.

layer containing the foregoing reagent system. A layer prepared accordlng to this example would have a pH Or above about 7Ø

U.S. Patent 3,983,005 de~cribes ln Example 3 the use of 4-aminoantipyrine and a naphthollc coupler ror the detection o~ hydrogen peroxide produced on contact with cholesterol oxidase ln an element of the type described herein. Accordlng to this example, the indicator reaction is carried out at a pH of 7Ø ;

~.S. Patent No. 3,~86,045 describes a test composltion for glucose assay comprlslng glucose oxidase, peroxldase, sodium or potassium ferrocyanide, an aminoantipyrine and a phenollc coupler. It is disclosed that such compositions,always lncluding the ferrocyanide, are useful when burrered at a pH of between about 5.5 and 8.o. There is no disclosure that compositions which omlt the ferrocyanide are useful throughout this pH range. This patent also includes an extensive discussion Or phenols useful ln analytical reagents of the type descrlbed hereln.

It has now been found that the aforementioned 6 interference of fluoride ion with glucose analyses perrormed ~ :

ln integral multilayer elements Or the type described in U.S. Patent No. 3,992,158 can be reduced or ellminated by bu~ferlng the reagent composition contained therein to a pH
between about 4.5 and 6Ø Although the mechanism ror this reduction or elimination Or ~luoride interference at this pH

- . -3-~. .
~.
': .
,. : ' 1$'~

is not completely understood, perrormance Or the assay reactlons within this pH range provldes the desired reduction or eliminatlon-Trinder's reagent for the detectlon Or glucose, which comprlses glucose oxldaseJ a substance havlng pero~ldatlve actlvlty, 4-amlnoantlpyrlne and a phenollc coupler, is well known ln the art and ls descrlbed ln detail ln the two Trinder publications rererred to above.
The detection Or glucose using Trlnder's reagent 10 is conventlonally carrled out at a pH of 7.0 or above.
However, at thls pH, fluorlde ion, whlch is used as a preservative ~or serum samples, acts as an lnterrerent when thls reagent is used ln an element Or the type described in U.S. Patent 3,992,158. Although the cause of thls phenomenon is not understood, we have discovered that the interference due to fluoride lon ln such multilayer elements can be reduced or ellmlnated by burfering the Trinder's - ~.
reagent system to a pH of between about 4~5 and 6Ø
Thus, the reagent composltions contalned in the 20 elements Or the lnstant invention comprlse Trinder's reagent . -or some modification thereof use~ul in the detection of glucose in an aqueous medium bu~ered to a pH of between about 4.5 and about 6.o.
Glucose oxidase and lts sources and preparation -~
are well known in the art and no ~urther discusslon thereor is neCessarY here. r 1, :

2~

Substances having peroxldative act~vlty ~hlch are useful in cllnical applications have been discussed at length in the prior art and are well known to the 6kllled artisan. One such discusslon is presented ln U.S.
Patent 3,884,764 at column 6, line 52, to column 7, llne 18. A prererred substance o~
this type is, of course, peroxidase, which has been used broadly in clinical analytical appllcations.
Aminoantipyrine, also ldentlfied as amlnophenazone, is an oxygen acceptor which, ln its oxldized state, couples with-a phenolic coupler. In the dry elements descrlbed herein, aminoa~tlpyrine is generally supplled ln the rorm Or an acid salt, ~or example, the hydrochlorlde salt. A discussion ~r aminoantipyrine ls presented in V.S. Patent No. 3,886,o45.
A preferred aminoantipyrlne ls 4-amlnoantlpyrlne.
A detailed discusslon o~ phenollc couplers includlng examples Or useful phenolic couplers ls presented by Mees, C. E. X., and James, T. H., The TheorY of the Photographlc Process, . . _ , .
Thlrd Ed., Macmillan Co., N.Y. (1966), p. 387fr and in the aforementioned U.S. Patent No. 3,886,o45. As ls apparent from the dlscusslons, phenollc couplers include both phenols and naphthols, both o~ which may be substltuted or unsubstltuted.
; Specifically, pre~erred from among such couplers is 7-hydroxy-l-naphthol. Thls coupler demonstrates outstandlng stabillty and reactivlty and provldes an indicator dye which absorbs at a convenient wavelength ror spectrophotometric measurement in the ~ormat indicated.
In order to provide an appropriate pH for the reaction to be carried out, a suitable bu~er must be lncluded . . .

, ` .

~L4 ~",f~i~

ln the reagent mixture. ~irtually any burrer that (1) buffers at a pH Or between about 4.5 and 6.o, (2) ls compatlble wlth the reagent co~posltlon andt3) ls sultable ~or lncorporatlon ln the elements descrlbed hereln according to the methods described ln arorementloned V.S. Patent 3,992,158 ls useful in the successful practlce of the lnstant lnvention. Such bufrers are described generally by Good, Biochemistry, ~, 467 (1966). Buffers that have been found useful lnclude dlmethylglutaric acids, succinic acld, mallc acid, potasslum acid phthalate and mixed phosphate-cltrate buffers. Speclfically preferred from among thls group is 3,3-dimethylglutarlc acid.
As used hereln, the term "integral element" refers to elements having at least two superposed layers, deslrably dlscrete, ln intimate contact. Preferably, such elements are formed prior to applicatlon of a llquid sample ~or analysis. Elements of thls lnvention are capable or perrorming internally a variety of sample-handling functions. They do not require expertise ln their use and can produce quantitative analytical results without the specialized spotting or other procedures, e.g. sample confinement, washing or removal o~ excess sample, typically needed for analyses made using ~nown elements. ~urther, the results ;~
produced by elements of thls lnvention are substantially ~ -conslstent and free from lnternal variatlons so that automated means of measurlng electromagnetlc radiation (radlometric technlques) can be used to detect such results with minlmal lnconsistency.
Stated more partlcularly, according to a preferred 3~ embodlment, tbe present lnventlon provldes lntegral analytlcal .

. , ~' ,, ' . .

elements for the detectlon of glucose, which elements are composed Or multiple, superposed layers whlch can provlde quickly within the element a hlghly quantltatlve dye productlon in response to the presence of fluoride-contalnlng solutions Or glucose applied to the element. Elements of thls lnventlon include a sample spreadlng layer ln fluld contact wlth a reagent l~yer. The sample spreading layer ls capable of dlstrlbutlng wlthln the layer glucose contalned ln a liquid sample applied to the element -to provide, at any given tlme, a unlrorm concentration of glucose at the surface Or the spreadlng layer raclng, l.e., closer to, the reagent layer. In varlous preferred embodiments, the spreading layer is isotropically porous; that is, it is porous in every direction within the layer. ~ererence herein to isotropic porosity identifies the fact Or substantial porosity in all directions withln the spreading layer. It ; will be understood that the degree Or such porosity may be variable, lr necessary or desirable, for example, regarding pore size, percentage Or vold volume or otherwlse. It shall be understood that the term "lsotropic poroslty" (or "isotroplcally porous") as used herein should not be con~used with the terms "isoporous" or "ionotroplc", o~ten used wlth reference to filter membranes to slgnlfy those membranes having pores that are continuous between membrane sur~aces. Likewlse, "lsotropic porosity" should not be conrused with the term "isotropic", used in contradistinction to the term "anisotropic", which signifies rilter membranes having a thln "skin" along at least onc sur~ace Or tùe membrane. See, ror example, :
. ' ~
~.

.

13L14'7~

Membrane Sclence and ~echnology, James Fllnn ed, Plenum Press, New York (1970).
The reagent layer ls a layer underlylng the spreadlng layer and containing the reagent compositions described herein, namely,glucose oxidase, a substance havlng peroxidative activity, amlnoantipyrine, a phenolic coupler and a burfer to maintain the pH of the layer between about 4.5 and 6.o when contacted with a test sample. 'l'he reagent layer is preferably of substantially uniform permeability to glucose contained in aqueous liquid applied to the spreadlng layer.
Uni~orm permeability Or the layer re~ers to permeability such that, when a homogeneous glucose solution ls provided uniformly to a surface of the layer, identical measurements of the co~centration Or glucose ln the solutlon within the layer, but made through different regions of a surface of the layer, will yield substantially equal results.
Reference herein to fluid contact between a spreading layer and a reagent layer ln an integral analytical element identi~ies the ability o~ a fluid, whether liquid or gaseous, to pass in such element between superposed regions of the spreading layer and the reagent layer. Stated in another manner, fluid contact re~ers to the ability to transport components of a fluid between the layers in fluid contact. Although such layers in fluld contact can be contiguous, they may also be separated by lntervening layers.
However, layers in the element that physically intervene a spreading layer and reagent layer ln mutual fluid contact wlll also be in fluid contact and will not prevent the passage of fluld between the fluid-contacting spreading and reagent la~ers.

:- : .. .

2~ :

The rollowing examples Or lntegral elements are provided to lllustrate further the practlce of the inventlon.

Examples 1-4: Reduced Fluoride Interference at Lower pH
Fvacuated blood containers, containlng either sodium fluorlde/oxalate or sodlum rluoride/EDTA as preservative, were partially or totally filled with blood samples; hence,the actual concentration of ~luoride ion present varied with each sample.
If the contalner was tota~y filled wlth a blood sample (l.e.g 7 cc), ;the amount of F present would be 250 mg/dl, if halr ~llled, 500 mg/dl. The glucose level of each sample was brought to ~350 mg/dl by spiking. The samples were then spotted (ln 10 ~1 allquots) onto test elements having the ~ollowing compositlon and which were prepared accordlng to the methods described in V.S. Patent No. 3,992,158.
Polyethylene terephthalate supports were coated with reagent layers comprislng deionized gelatin (21.5 g/m2), peroxidase (10,000 U/m2) glucose oxidase (24,400 U/m2), 4-aminoantlpyrine-HCl (0.86 g/m2), 7-hydroxy-1-naphthol (0.66 g/m2) and 3,3-dimethylglutaric acid (1.96 g/m ) (pH varied with each element as shown in Table 1). A
subblng layer comprising poly-n-isopropylacrylamlde and a :
4 ~ ~

spreading layer comprlslng cellulose acetate (6.6 g~m2) and TiO2 (46 g/m2) were then applled.
Arter 7 min. at 37~C., the reflectlon densltles produced were measured and a callbratlon curve Or reflectlon density vs. glucose concentratlon plotted ror each element. The rerlection densities obtained were then checked agalnst the derived calibration curves ànd the corresponding apparent glucose concentration was obtained. The difrerence between the glucose concentratlon Or the callbratlon curves and the glucose concentration as determined according to a conventional rererence method is shown in Table 1.

.
: . .,.:

.
,: ~ . -- ~

~4'~

0 1 0 1~ N
td ~:q 1*.1 J

E-~ ~
a C c~ o o o ~ Q~
L~ ~t ~ ~ 3 C ~ J~:J
~O ~ ~t~r _~ a~
a: .
O
~( ~:: 1~ ~ E

o E
0 ~ ....
~o ~ ~ o o C ~ ~ Lr~
r~
D

O

....
~1 ~ _I u~co m I ~ ~
~I ~ ~ ~
a~ 0 ~I _~
D 3 J~ a~
u~ ~ ~ oooo x c~
~ o s~ ~ ~ ~ ~u C) ~ Q) U~
~: a~ ~ ~ ~ ~ r~
~ _l ~ .
a~ ~ ~1 ~ 3 a ~1 .
1~ E E

~ --t ~ cr~
_I
~ M C~ II~C~
O ~ a ~

3 D ~ ~ ~.
~ :~ ~ . ' ' .
' :~ 1 o ~
. . .
-'::
.
O
Z : ::
O
_~ ~ )J
~ . ,~.

-: ' ' .. .. - .
. : ' ' : ' ' ' ' ~
.
.
.

Example 5: Effect Or ~H and Fluorlde Interrerence on Rate Or Develo~ment Elements prepared ln the same manner as ln Examples 1-4, also varying ln pH (5.0 and 7.0)~ were evaluated ln the manner described in Examples 1-4, using serum containlng no fluoride ion, plasma contalning 2.5 mg/dl fluoride/EDTA and plasma contalning ~5.0 mg/dl rluorlde/EDTA.
The rates of dye development (DR) vs. tlme Or the elements were compared in Figs. 1 and 2. The rates for each sample were much slower at pH 7.0, while at pH 5.0 they di~fered only in the early stages Or dye development.

Examples 6~ Effect of Serum_pH Upon Element Res~onse A series Or elements was prepared as in Examples 1-4, but using three dirferent burfer systems: dimethylglutarate (1.96 g/m2), succinlc acld (1.40 g/m2) or mallc acld (1.58 - g/m2) (pH is indicated in Table 2).
Two samples Or sera containing 100 mg/dl and 400 mg/dl glucose were each adJusted to a pH of 7.7 and 8.6.
The samples were then spotted onto the test elements and evaluated as in Example 1. Results shown ln Table 2 suggest that the elements, as prepared, have adequate bu~fering capacity and can tolerate fluctuations that may occur ln the pH Or serum.

.

.- .., . -' - !

- . .. .-' a~ l ~ o u~
~ O ~1 0 _I
.~ 1''' . .
bO Cl:l C~ C~ ) 3 E 11 ......
O G ~ ~1~ _I ~1 ~1 C .
V~ ~ ~D ~ ~ac~
~D U~ : ~ ~ ~1 ll N N N N N N
Q
QJ
C~
c a~;¦ o ~u~
U~ 00_100~1 P: . 1~++
D ~1 a~ ~
3 ~ ~D
~: bi~ o~ N O O ~ N Lr~
~ O E co o~ o c~ u~
t~ tr) ~3 Q) ::~ oo :~: ......
D :~ ~1 E-~ E 6 ~ _~
.: ~ ~ ~ ~.
Cq ~1 t-- N ~11~ ~ O~ ~1 a~ ~ o ~ Ir~ ' -~)~ t~
O ......
X
C~
C~

C~ t) a~ c~
_~ td ~ : :
C~ ~
m c~
E Cl 0 0 6 E

:~ I o U~ o U~ o U~

a~ . :
E ~ o ,1 K _I _I . - .
.
.. .

:

Claims (4)

We claim:
1. An integral element for the determination of glu-cose in aqueous liquids, said element comprising a spreading layer and a reagent layer in fluid contact under conditions of use and containing Trinder's reagent as the glucose-determining reagent composition, Trinder's reagent comprising a substance having peroxidase activity, 4-aminoantipyrine and a phenolic or naphtholic coupler, said element characterized by the inclusion of a buffer which maintains the pH of the reagent composition between about 4.5 and 6.0 under conditions of use.
2. The element of Claim 1 wherein said substance having peroxidative activity is peroxidase.
3. The element of Claim 1 wherein said coupler is 7-hydroxy-1-naphthol.
4. The element of Claim 1 wherein the buffer is selected from the group consisting of dimethylglutaric acid, succinic acid, potassium acid phthalate, malic acid and mixed phosphate-citrate buffer.
CA307,795A 1977-08-01 1978-07-20 Glucose detection system free from fluoride-ion interference Expired CA1114723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US821,028 1977-08-01
US05/821,028 US4098574A (en) 1977-08-01 1977-08-01 Glucose detection system free from fluoride-ion interference

Publications (1)

Publication Number Publication Date
CA1114723A true CA1114723A (en) 1981-12-22

Family

ID=25232322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA307,795A Expired CA1114723A (en) 1977-08-01 1978-07-20 Glucose detection system free from fluoride-ion interference

Country Status (6)

Country Link
US (1) US4098574A (en)
JP (1) JPS5426793A (en)
CA (1) CA1114723A (en)
DE (1) DE2833741A1 (en)
FR (1) FR2399662A1 (en)
GB (1) GB2001758B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856487A1 (en) * 1977-12-29 1979-07-12 Wako Pure Chem Ind Ltd PROCEDURE FOR DETERMINING PEROXID SUBSTANCES AND COMPOUNDS THAT CAN BE USED THEREFORE
JPS5520471A (en) * 1978-08-01 1980-02-13 Kyowa Hakko Kogyo Co Ltd Hydrogen peroxide quantifying method
IT1099355B (en) * 1978-10-12 1985-09-18 Sclavo Inst Sieroterapeut COMPOSITION SUITABLE FOR THE DETERMINATION OF GLUCOSE IN KINETICS
DE2964377D1 (en) * 1978-11-15 1983-01-27 Battelle Memorial Institute Analytical process and means for measuring the amount of hydrogen peroxide in aqueous media and of organic substrates generating hydrogen peroxide by enzymatic oxidation
US4307188A (en) * 1979-09-06 1981-12-22 Miles Laboratories, Inc. Precursor indicator compositions
US4399218A (en) * 1980-02-05 1983-08-16 Boehringer Mannheim Gmbh Method and reagent for the determination of glycerin
JPS5794656A (en) * 1980-12-04 1982-06-12 Konishiroku Photo Ind Co Ltd Element for analysis
JPS57174099A (en) * 1981-04-17 1982-10-26 Fuji Photo Film Co Ltd Color indicator composition for detecting hydrogen peroxide and quantitative analytical film having reagent layer containing the same
DE3125667C2 (en) * 1981-06-30 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Method and means for the detection of hydrogen peroxide
US4427770A (en) 1982-06-14 1984-01-24 Miles Laboratories, Inc. High glucose-determining analytical element
JPS5920853A (en) * 1982-07-28 1984-02-02 Fuji Photo Film Co Ltd Multi-layer analysis material
US4460684A (en) * 1982-08-02 1984-07-17 Miles Laboratories, Inc. Ascorbate-resistant broad range glucose test composition, test device and method
JPS5946854A (en) 1982-09-10 1984-03-16 Fuji Photo Film Co Ltd Multilayered analytical material
US4637978A (en) * 1983-10-28 1987-01-20 Eastman Kodak Company Assay for analysis of whole blood
JPS60108753A (en) * 1983-11-18 1985-06-14 Fuji Photo Film Co Ltd Multilayer chemical analysis element
JPS60162957A (en) * 1984-02-03 1985-08-24 Kyowa Medetsukusu Kk Method for measuring ceruloplasmin activity
US4548905A (en) * 1984-04-09 1985-10-22 Eastman Kodak Company Reagent composition, dry element and method for determination of total bilirubin
JPH0687062B2 (en) * 1985-05-10 1994-11-02 株式会社京都医科学研究所 How to prevent glycolysis in blood
US4935346A (en) 1986-08-13 1990-06-19 Lifescan, Inc. Minimum procedure system for the determination of analytes
JPS6353465A (en) * 1986-08-25 1988-03-07 Konica Corp Analyzing element
US4994238A (en) * 1988-06-09 1991-02-19 Daffern George M Constant volume chemical analysis test device
US5264105A (en) * 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5264104A (en) * 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5320725A (en) * 1989-08-02 1994-06-14 E. Heller & Company Electrode and method for the detection of hydrogen peroxide
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5262305A (en) * 1991-03-04 1993-11-16 E. Heller & Company Interferant eliminating biosensors
CA2050057A1 (en) * 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
JP3394262B2 (en) 1997-02-06 2003-04-07 セラセンス、インク. Small volume in vitro analyte sensor
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6251260B1 (en) 1998-08-24 2001-06-26 Therasense, Inc. Potentiometric sensors for analytic determination
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6654625B1 (en) 1999-06-18 2003-11-25 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
ATE342497T1 (en) * 2000-08-01 2006-11-15 Charm Sciences Inc HYGIENE MONITORING
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US20100213057A1 (en) 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
EP2549918B2 (en) 2010-03-24 2023-01-25 Abbott Diabetes Care, Inc. Medical device inserters and processes of inserting and using medical devices
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
AU2012335830B2 (en) 2011-11-07 2017-05-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP4056105B1 (en) 2011-12-11 2023-10-11 Abbott Diabetes Care, Inc. Analyte sensor devices
CA2984939A1 (en) 2015-05-14 2016-11-17 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
CN110461217B (en) 2017-01-23 2022-09-16 雅培糖尿病护理公司 Systems, devices, and methods for analyte sensor insertion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2982700A (en) * 1961-05-02 Diagnostic composition
US2848308A (en) * 1955-12-05 1958-08-19 Miles Lab Composition of matter
US3104209A (en) * 1960-02-02 1963-09-17 Fermco Lab Inc Composition for determination of glucose
US3278394A (en) * 1963-07-22 1966-10-11 Miles Lab Method and composition for diagnosing glucose
CH548029A (en) * 1971-03-30 1974-04-11 Hoffmann La Roche MEANS OF DETECTING GLUCOSE.
IT986838B (en) * 1972-05-12 1975-01-30 Sclavo Inst Sieroterapeut COMPLEX OF REAGENTS FOR THE ENZYMATIC DETER MINATION OF GLUCOSE GLUCOSE SYSTEM OXIDASE PEROXIDASE DASES WITH MANUAL AND AUTOMATED METHODS CO WITH READING AT TERM OR IN KINETICS
DE2332760C3 (en) * 1972-06-30 1982-03-04 Eastman Kodak Co., 14650 Rochester, N.Y. Material for the quantitative spectrophotometric analysis of a liquid
US3992158A (en) * 1973-08-16 1976-11-16 Eastman Kodak Company Integral analytical element
US3884764A (en) * 1974-03-25 1975-05-20 Eastman Kodak Co Method and composition for blood serum cholesterol analysis
US3983005A (en) * 1974-03-25 1976-09-28 Eastman Kodak Company Integral element for the analysis of cholesterol
US3964870A (en) * 1974-03-29 1976-06-22 Boehringer Mannheim G.M.B.H. Diagnostic composition for the determination of glucose

Also Published As

Publication number Publication date
DE2833741A1 (en) 1979-02-15
FR2399662B1 (en) 1983-03-18
DE2833741C2 (en) 1988-01-14
GB2001758B (en) 1982-02-03
FR2399662A1 (en) 1979-03-02
JPS5728277B2 (en) 1982-06-15
JPS5426793A (en) 1979-02-28
GB2001758A (en) 1979-02-07
US4098574A (en) 1978-07-04

Similar Documents

Publication Publication Date Title
CA1114723A (en) Glucose detection system free from fluoride-ion interference
EP0071934B1 (en) Method for preparing a color stable chromogenic analytical element
EP0101799B1 (en) High glucose-determining analytical element
EP0230229B1 (en) Stable composition for the determination of peroxidatively active substances
FI81119C (en) Test strip for ethanol determination, alcohol oxidase composition and ethanol assay method
EP0345781B1 (en) Defined volume test device
US4781890A (en) Multilayer chemical analytical element
US4273868A (en) Color stable glucose test
EP0382207B1 (en) Analytical element for whole blood
US4594224A (en) Analytical element
EP0256562A2 (en) Dry-type multilayer analytical element
US4567024A (en) Analytical element
JP2950592B2 (en) Multilayer analytical tool for fructosamine measurement
USH623H (en) Integral multilayer analysis element
EP0244825B1 (en) Dry-type analytical element for cholesterol
EP0117032A1 (en) Rapid analysis of ethanol in body fluids
US4567136A (en) Analytical element
EP0158507B1 (en) Reagent composition, dry element and method for determination of total bilirubin
EP0629705B1 (en) Reagent composition for quantitative analysis of inorganic phosphorus and dry analysis element utilizing the same
JPH05260994A (en) Detection of analyte in saliva using peroxide-peroxidase test system
EP0579331B1 (en) Dry analytical element and method for the colorimetric determination of lithium ion
EP0272578B1 (en) Multilayer analysis elements for the determination of total cholesterol
EP0811844A1 (en) Reagent composition, testing piece and assay kit
JP2006087325A (en) Analytical reagent, dry analytical element and analytical method
JPH0578318B2 (en)

Legal Events

Date Code Title Description
MKEX Expiry